Staidson

Staidson(Beijing)Biopharmaceuticals Co.,Ltd., formerly known as Staidson (Beijing) Pharmaceutical Co., Ltd. which was established in August 2002, was restructured into a joint-stock company in May 2009 and renamed "Staidson(Beijing)Biopharmaceuticals Co.,Ltd." The company focuses on the research, production, and marketing of innovative drugs with independent intellectual property rights. It falls under the "C27 Pharmaceutical Manufacturing" category in the industry classification of listed companies by the China Securities Regulatory Commission. Staidson is an innovative biopharmaceutical enterprise covering the entire industrial chain from early exploratory research, drug discovery, process development and pilot-scale production, preclinical biological evaluation, clinical development to drug manufacturing and commercialization. The company has complete systems for R&D, production, and marketing and is a national-level high-tech enterprise.The company is committed to the R&D, production, and sales of therapeutic drugs that address unmet clinical needs, mainly including three major categories: protein-based drugs (including therapeutic monoclonal antibody drugs), gene therapy/cell therapy drugs, and chemical drugs. Its therapeutic areas cover a variety of fields such as nervous system-related diseases, infectious diseases, gastrointestinal diseases, urinary system diseases, and autoimmune diseases.